Jan 12, 2023 / 08:00PM GMT
Unidentified Analyst -
Welcome, everyone. Thank you for being here. I'm (inaudible) from JPM. We have with us here today, CEO of Xeris Pharma, Paul Edick.
Paul R. Edick - Xeris Biopharma Holdings, Inc. - Chairman & CEO
Thank you. Welcome, everybody. I'm going to give you the overview on Xeris, and then we'll have a Q&A. Xeris is a growth-oriented biopharma company committed to improving the lives of -- and developing and commercializing assets in both rare and specialty areas. I would remind everyone to pay attention to our forward-looking statements. Investing is always a risk.
Let's start off with an overview of the company. Xeris has a very diversified revenue base. We have 3 marketed assets, all growing. RECORLEV, I'll talk a little bit about. It's in the launch stage. And this year, we have guided to $105 million -- or 2022, we've guided to $105 million to $110 million. We'll finish at the top end of that range.
We have a specialized commercial platform in endocrinology and in neurology, and we'll go into some of the products. Our
Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers